Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use

PLoS ONE

Volumn 4, Issue 6, 2009, Pages

  Le, Thuy ^a   Chiarella, Jennifer ^a   Simen, Birgitte B ^b   Hanczaruk, Bozena ^b   Egholm, Michael ^b   Landry, Marie L ^a   Dieckhaus, Kevin ^c   Rosen, Marc I ^a,d   Kozal, Michael J ^a,d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b 454 Life Sciences/Roche ^*  (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; NELFINAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; COMPLEMENTARY DNA; VIRUS RNA;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESISTANT MUTATION; DRUG USE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; PYROSEQUENCING; SANGER SEQUENCING; TREATMENT FAILURE; ULTRA DEEP PYROSEQUENCING; VIRUS LOAD; ALGORITHM; METABOLISM; MUTATION; PREVALENCE; RISK; VIROLOGY; VIRUS REPLICATION;

ALGORITHMS; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; DNA, COMPLEMENTARY; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HUMANS; MUTATION; ODDS RATIO; PREVALENCE; RNA, VIRAL; VIRUS REPLICATION;

EID: 67650682133     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006079     Document Type: Article

References (35)

1. Dykes C, Najjar J, Bosch RJ, Wantman M, Furtado M, et al. (2004) Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine. J Infect Dis 189(6): 1091-1096.
2. Kapoor A, Jones M, Shafer RW, Rhee SY, Kazanjian P, et al. (2004) Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assay. J Virol 78(13): 7112-7123.
3. Lalonde MS, Troyer RM, Syed AR, Bulime S, Demers K, et al. (2007) Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies. J Clin Microbiol 45(8): 2604-2615.
4. Lecossier D, Shulman NS, Morand-Joubert L, Shafer RW, Joly V, et al. (2005) Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acquir Immune Defic Syndr 38(1): 37-42.
5. Metzner KJ, Bonhoeffer S, Fischer M, Karanicolas R, Allers K, et al. (2003) Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis 188(10): 1433-1443.
6. Metzner KJ, Rauch P, Walter H, Boesecke C, Zollner B, et al. (2005) Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS 19(16): 1819-1825.
7. Palmer S, Boltz V, Maldarelli F, Kearney M, Halvas EK, et al. (2006) Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS 20(5): 701-710.
8. Roquebert B, Malet I, Wirden M, Tubiana R, Valantin MA, et al. (2006) Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors. AIDS 20(2): 287-289.
9. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW (2007) Characterization of mutation spectra with ultra-deep pyrosequencing: Application to HIV-1 drug resistance. Genome Res 17(8): 1195-1201.
10. Korn K, Reil H, Walter H, Schmidt B (2003) Quality control trial for human immunodeficiency virus type 1 drug resistance testing using clinical samples reveals problems with detecting minority species and interpretation of test results. J Clin Microbiol 41(8): 3559-3565.
11. Schuurman R, Brambilla D, de Groot T, Huang D, Land S, et al. (2002) Underestimation of HIV type 1 drug resistance mutations: Results from the ENVA-2 genotyping proficiency program. AIDS Res Hum Retroviruses 18(4): 243-248.
12. Coffin JM (1995) HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 267(5197): 483-489.
13. Flys T, Nissley DV, Claasen CW, Jones D, Shi C, et al. (2005) Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 192(1): 24-29.
14. Paredes R, Lalama C, Ribaudo HJea (2008) Presence of minor populations of Y181C mutants detected by allele-specific PCR and risk of efavirenz failure in treatment-naive patients: Results of an ACTG5095 case-cohort study. 15th Conference of Retroviruses and Opportunistic Infections. Boston Feb 3-6: Abstract 83.
15. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, et al. (2008) Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 5(7): e158.
16. Simen B, Simons J, Hullsiek K, Novak R, MacArthur R, et al. (2009) Low-Abundance Drug-Resistant viral variants in chronically HIV-Infected, antiretroviral Treatment - Naive patients significantly impact treatment outcomes. J Infect Dis 199(5): 693-701.
17. Metzner KJ, Giulieri SG, Knoepfel SA, Rauch P, Burgisser P, et al. (2009) Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin Infect Dis 48(2): 239-247.
18. Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, et al. (2005) Genome sequencing in microfabricated high-density picolitre reactors. Nature 437(7057): 376-380.
19. Rosen MI, Dieckhaus K, McMahon TJ, Valdes B, Petry NM, et al. (2007) Improved adherence with contingency management. AIDS Patient Care STDS 21(1): 30-40.
20. Kozal MJ, Shah N, Shen N, Yang R, Fucini R, et al.(1996) Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 2(7): 753-759.
21. Kozal MJ, Amico KR, Chiarella J, Cornman D, Fisher W, et al. (2006) A population-based and longitudinal study of sexual behavior and multidrug-resistant HIV among patients in clinical care. MedGenMed 8(2): 72.
22. Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, et al. (2008) Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an international AIDS society-USA panel. Clinical Infectious Diseases 47(2): 266-285.
23. Stenman J, Lintula S, Rissanen O, Finne P, Hedstrom J, et al. (2003) Quantitative detection of low-copy-number mRNAs differing at single nucleotide positions. BioTechniques 34(1): 172-177.
24. Thomas RK, Nickerson E, Simons JF, Janne PA, Tengs T, et al. (2006) Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 12(7): 852-855.
25. Mitsuya Y, Varghese V, Wang C, Liu TF, Holmes SP, et al. (2008) Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations. J Virol 82(21): 10747-10755.
26. Hanna GJ, Johnson VA, Kuritzkes DR, Richman DD, Brown AJ, et al. (2000) Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J Infect Dis 181(3): 904-911.
27. Marcelin AG, Delaugerre C, Wirden M, Viegas P, Simon A, et al. (2004) Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J Med Virol 72(1): 162-165.
28. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, et al. (2005) Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 43(1): 406-413.
29. Devereux HL, Emery VC, Johnson MA, Loveday C (2001) Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. J Med Virol 65(2): 218-224.
30. Paredes R, Sagar M, Marconi VC, Hoh R, Martin JN, et al. (2009) In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. J Virol 83(4): 2038-2043.
31. Kuritzkes DR (2001) A fossil record of zidovudine resistance in transmitted isolates of HIV-1. Proc Natl Acad Sci U S A 98(24): 13485-13487.
32. Harrigan PR, Wynhoven B, Brumme ZL, Brumme CJ, Sattha B, et al. (2005) HIV-1 drug resistance: Degree of underestimation by a cross-sectional versus a longitudinal testing approach. J Infect Dis 191(8): 1325-1330.
33. Yerly S, Michel PA, Emler S, et al. (2008) Cross-sectional versus cumulative interpretation of HIV-1 drug resistance mutations. Antivir Ther 13(3): A110.
34. Zaccarelli M, Lorenzini P, Tozzi Vea (2008) Are current or archived resistance mutations predictive of treatment failure in heavily pre-treated HIV patients? 6th European HIV Drug Resistance Workshop. March 26-28. Budapest. pp Abstract 42.
35. Shafer RW, Levee DJ, Winters MA, Richmond KL, Huang D, et al. (1997) Comparison of QIAamp HCV kit spin columns, silica beads, and phenol-chloroform for recovering human immunodeficiency virus type 1 RNA from plasma. J Clin Microbiol 35(2): 520-522.